NMTC NEUROONE MEDICAL TECHNOLOGIES Corp

  1. Stocks
  2. Healthcare
  3. NASDAQ: NMTC

Price (delayed)

$1.9

Market cap

$16.54M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.88

Enterprise value

$13.82M

?
Relative Growth: Rel. Growth: 59
Relative Strength: Rel. Strength: 3
Relative Valuation: Rel. Valuation: 22
Relative Profitability: Rel. Profitability: 18
Highlights
The company's debt has shrunk by 55% YoY and by 16% QoQ
The EPS has grown by 34% year-on-year and by 15% since the previous quarter
The quick ratio has soared by 199% YoY but it is down by 44% QoQ
NEUROONE MEDICAL TECHNOLOGIES's gross profit has decreased by 18% YoY but it has increased by 4.6% QoQ
The gross margin is down by 22% YoY
NEUROONE MEDICAL TECHNOLOGIES's equity has decreased by 21% from the previous quarter
Sector: Healthcare
Industry: Medical Devices
Peers: OBIO OM

Key stats

What are the main financial stats of NMTC

NMTC stock price

How has the NEUROONE MEDICAL TECHNOLOGIES stock price performed over time
Intraday
2.7%
1 week
-18.8%
1 month
-41.9%
1 year
-64.88%
YTD
-58.24%
QTD
-37.5%

Financial performance

How have NEUROONE MEDICAL TECHNOLOGIES's revenue and profit performed over time
Revenue
$9.19M
Gross profit
$5M
Operating income
-$7.36M
Net income
-$6.94M
Gross margin
54.4%
Net margin
-75.5%
The gross margin is down by 22% YoY
NEUROONE MEDICAL TECHNOLOGIES's gross profit has decreased by 18% YoY but it has increased by 4.6% QoQ
The company's operating income fell by 12% YoY but it rose by 3.7% QoQ
NMTC's operating margin is up by 9% from the previous quarter but it is down by 7% YoY

Price vs fundamentals

How does NMTC's price correlate with its fundamentals

Growth

What is NEUROONE MEDICAL TECHNOLOGIES's growth rate over time

Valuation

What is NEUROONE MEDICAL TECHNOLOGIES stock price valuation
P/E
N/A
P/B
3.15
P/S
1.75
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.5
The EPS has grown by 34% year-on-year and by 15% since the previous quarter
The P/B is 60% below the 5-year quarterly average of 7.8 and 48% below the last 4 quarters average of 6.0
NEUROONE MEDICAL TECHNOLOGIES's equity has decreased by 21% from the previous quarter
The price to sales (P/S) is 94% lower than the 5-year quarterly average of 31.5 and 54% lower than the last 4 quarters average of 3.8
NMTC's revenue is up by 5% since the previous quarter and by 4.9% year-on-year

Efficiency

How efficient is NEUROONE MEDICAL TECHNOLOGIES business performance
The return on equity has surged by 69% year-on-year and by 13% since the previous quarter
NMTC's ROA is up by 41% YoY and by 7% from the previous quarter
The company's return on invested capital rose by 14% QoQ and by 9% YoY
The ROS has grown by 3.6% since the previous quarter

Dividends

What is NMTC's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for NMTC.

Financial health

How did NEUROONE MEDICAL TECHNOLOGIES financials performed over time
The quick ratio has soared by 199% YoY but it is down by 44% QoQ
NMTC's current ratio has surged by 98% year-on-year but it is down by 34% since the previous quarter
The company's debt is 98% lower than its equity
NMTC's debt to equity has shrunk by 89% YoY
The company's debt has shrunk by 55% YoY and by 16% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.